Module 1: Initiating HIV Therapy: Are We Now in an Integrase-Based World?

This CME/CE-accredited CME Snapshot™ four-part series is intended for infectious disease physicians and other clinicians who manage patients with HIV. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with HIV.

Target Audience

This activity has been designed to meet the educational needs of infectious disease physicians and other clinicians who manage patients with HIV.

Educational Objectives 

Upon completion of this activity, participants will be better able to do the following:

  1. Recommend guideline-concordant initial antiretroviral therapy (ART) regimens to patients with HIV based on clinical and laboratory findings and evidence for efficacy, safety, tolerability, genetic barriers to resistance, and treatment adherence
  2. Discuss clinical data on emerging HIV-treatment paradigms, including novel medication combinations and drug-delivery or dosing methods to simplify ART regimens

Faculty

Paul E. Sax, MD—Program Chair
Clinical Director, Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine 
Harvard Medical School 
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Director, Clinical Core

Penn Center for AIDS Research
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosure of Conflicts of Interest

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of Integritas Communications and Purdue University College of Pharmacy have no relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Paul E. Sax, MDHas nothing to disclose
Ian Frank, MD

Consultant/Advisor: Gilead Sciences, Inc., ViiV Healthcare

Grant/Research Support: Janssen Pharmaceuticals, Inc.

Non-faculty: Gena Dolson, MS hereby states that neither she nor her spouses/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from ViiV Healthcare.

Provider Information

Jointly provided by Purdue University and Integritas Communications.

 

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Integritas Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™ for each module. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Individual Universal Activity Numbers (UAN), titles and credits listed below for each module.

Pharmacist Accreditation Statement - Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Module 1: Initiating HIV Therapy: Are We Now in an Integrase-Based World?
UAN: 0018-9999-18-079-H01-P               .25 contact hours (.025 CEU)

CME Inquiries/Special Needs

Any accreditation questions may be directed to Dawn Sinclair at Purdue University via email sinclaid@purdue.edu. Questions regarding CE credit and CPE Monitor should be directed to Heather Holley via email at hholley@purdue.edu.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, Purdue University, and ViiV Healthcare do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.25 ACPE
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician
Course opens: 
06/01/2018
Course expires: 
05/31/2019
Rating: 
0

Available Credit

  • 0.25 ACPE
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician

Accreditation Period

Course opens: 
06/01/2018
Course expires: 
05/31/2019
Please login or register to take this course.